Drug details
Infugem (gemcitabine in sodium chloride injection)
type of Antineoplastics, Antimetabolite
Infugem (gemcitabine in sodium chloride injection) is a nucleoside metabolic inhibitor indicated in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy; in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated; in combination with cisplatin for the treatment of non-small cell lung cancer; and as a single agent for the treatment of pancreatic cancer.
This drug may have the following side effects:
- nausea,
- rash,
- vomiting,
- shortness of breath,
- diarrhea,
- blood in the urine,
- fever,
- bleeding,
- infection,
- hair loss,
- low white blood cell count (neutropenia),
- low platelet count (thrombocytopenia),
- swelling and sores inside the mouth,
- Numbness and tingling
- anemia,
- swelling of the extremities,
- elevated liver enzymes,
- increased alkaline phosphatase,
- protein in the urine,
- drowsiness, and
The following drugs are related to Infugem, either as a replacement or used together:
- Krazati (adagrasib tablets)
- Alkeran (melphalan)
- Alkeran Injection (melphalan hcl injection)
- Alymsys (bevacizumab-maly injection)
- Avastin (bevacizumab)
- Cisplatin (cisplatin injection)
- Orserdu (elacestrant tablets)
- Lumakras (sotorasib tablets)
- Lynparza (olaparib capsules for oral administration)
- Margenza (margetuximab-cmkb injection, for intravenous use)
- Zejula (niraparib capsules)
- Paclitaxel Tablets (paclitaxel)
- Retevmo (selpercatinib capsules)
- Tepmetko (tepotinib tablets)
- Thiotepa (thiotepa injection)
- Tukysa (tucatinib tablets)